{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:26:18Z","timestamp":1791257178015,"version":"4.1.0"},"reference-count":94,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2016,1,2]]},"DOI":"10.1517\/14740338.2016.1112375","type":"journal-article","created":{"date-parts":[[2015,11,11]],"date-time":"2015-11-11T09:48:12Z","timestamp":1447235292000},"page":"43-52","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":80,"title":["Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?"],"prefix":"10.1517","volume":"15","author":[{"given":"Giuseppe","family":"Murdaca","sequence":"first","affiliation":[{"name":",","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Span\u00f2","sequence":"additional","affiliation":[{"name":",","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Contatore","sequence":"additional","affiliation":[{"name":",","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Guastalla","sequence":"additional","affiliation":[{"name":",","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Penza","sequence":"additional","affiliation":[{"name":",","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ottavia","family":"Magnani","sequence":"additional","affiliation":[{"name":",","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Puppo","sequence":"additional","affiliation":[{"name":",","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2015,11,11]]},"reference":[{"key":"e_1_3_1_2_1","unstructured":"Papers of special note have been highlighted as either of interest (\u2022) or of considerable interest (\u2022\u2022) to readers."},{"key":"e_1_3_1_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/039463200902200301"},{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4892(03)00032-8"},{"key":"e_1_3_2_3_1","first-page":"1035","article-title":"Clinical use of anti-TNF-alpha biological agents--a guide for GPs","volume":"36","author":"Chang J","year":"2007","unstructured":"Chang J, Girgis L. Clinical use of anti-TNF-alpha biological agents--a guide for GPs. Aust Fam Physician. 2007;36:1035\u20131038.","journal-title":"Aust Fam Physician"},{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2012.630388"},{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.07.006"},{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2011.47.4.1576692"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2005.04.016"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2013.823947"},{"key":"e_1_3_6_2_1","first-page":"43","article-title":"Long term treatment of rheumatoidarthritis with adalimumab","volume":"5","author":"Murdaca G","year":"2013","unstructured":"Murdaca G, Span\u00f2 F, Puppo F. Long term treatment of rheumatoidarthritis with adalimumab. Open Access Rheum Res Rev. 2013;5:43\u201349.","journal-title":"Open Access Rheum Res Rev"},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2004.11.006"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.2165\/11311040-000000000-00000"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt.13.173"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2014.899579"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2014.872238"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100665"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90372-7"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2011.0120"},{"issue":"4","key":"e_1_3_6_11_1","doi-asserted-by":"crossref","first-page":"iv2","DOI":"10.1136\/ard.2005.044941","article-title":"Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005","volume":"64","author":"Furst DE","year":"2005","unstructured":"Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis. 2005;64(Suppl 4):iv2\u201314.","journal-title":"Ann Rheum Dis"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2006.12.002"},{"key":"e_1_3_7_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh514"},{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-011-0517-7"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1984"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.2.1072"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1313.013"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12161"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000124720.18538.DD"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2012.05.013"},{"key":"e_1_3_8_2_1","doi-asserted-by":"publisher","DOI":"10.1179\/1351000213Y.0000000046"},{"key":"e_1_3_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2008.10.002"},{"key":"e_1_3_8_4_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1422.014"},{"key":"e_1_3_8_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000168925.98963.ef"},{"key":"e_1_3_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2012.02.002"},{"key":"e_1_3_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2009.219"},{"key":"e_1_3_8_8_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt.12.151"},{"key":"e_1_3_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2008.05.010"},{"key":"e_1_3_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2008.01727.x"},{"key":"e_1_3_9_4_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2013.755957"},{"key":"e_1_3_9_5_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.1009036"},{"key":"e_1_3_9_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-006-0183-7"},{"key":"e_1_3_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2011.08.001"},{"key":"e_1_3_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.10.020"},{"key":"e_1_3_10_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20899"},{"key":"e_1_3_10_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365520802699278"},{"key":"e_1_3_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2012.05057.x"},{"issue":"30","key":"e_1_3_11_2_1","first-page":"1672","article-title":"The formation of infliximab and anti-infliximab immune complexes as an explanation for non-responding to infliximab treatment of rheumatoid arthritis: observational study in 4 patients","volume":"152","author":"Van der Laken CJ","year":"2008","unstructured":"Van der Laken CJ, Voskuyl AE, Roos JC, et al. The formation of infliximab and anti-infliximab immune complexes as an explanation for non-responding to infliximab treatment of rheumatoid arthritis: observational study in 4 patients. Ned Tijdschr Geneeskd. 2008;152(30):1672\u20131677.","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"5","key":"e_1_3_11_3_1","first-page":"834","article-title":"Combination treatment with infliximab and leflunomide in patients with active rheumatoid arthritis: safety and efficacy in an open-label clinical trial","volume":"26","author":"Kalden JR","year":"2008","unstructured":"Kalden JR, N\u00fcsslein HG, Wollenhaupt J, et al. Combination treatment with infliximab and leflunomide in patients with active rheumatoid arthritis: safety and efficacy in an open-label clinical trial. Clin Exp Rheumatol. 2008;26(5):834\u2013840.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_11_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket260"},{"key":"e_1_3_11_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W"},{"key":"e_1_3_11_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22214"},{"key":"e_1_3_11_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200828"},{"key":"e_1_3_11_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005176-200405000-00008"},{"key":"e_1_3_11_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.072397"},{"key":"e_1_3_12_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2009.02280.x"},{"key":"e_1_3_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.07.033"},{"key":"e_1_3_12_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/370367a0"},{"key":"e_1_3_12_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/039463200802100214"},{"key":"e_1_3_12_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12098"},{"key":"e_1_3_12_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04682.x"},{"key":"e_1_3_12_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00005-012-0189-7"},{"key":"e_1_3_12_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.030452"},{"key":"e_1_3_12_10_1","doi-asserted-by":"publisher","DOI":"10.5414\/CPP48297"},{"key":"e_1_3_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2009.09.269"},{"key":"e_1_3_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.06.002"},{"key":"e_1_3_12_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12507"},{"key":"e_1_3_12_14_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i17.5031"},{"key":"e_1_3_12_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-006-0183-7"},{"key":"e_1_3_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60363-4"},{"key":"e_1_3_12_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.406"},{"key":"e_1_3_12_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.10139.x"},{"key":"e_1_3_13_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108787"},{"key":"e_1_3_13_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204185"},{"key":"e_1_3_14_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.07.062"},{"key":"e_1_3_14_3_1","first-page":"333","article-title":"Correlation between atopy and hypersensitivity reactions during therapy with three different TNF-\u03b1 blocking agents in rheumatoid arthritis","volume":"27","author":"Benucci M","year":"2009","unstructured":"Benucci M, Manfredi M, Saviola G, et al. Correlation between atopy and hypersensitivity reactions during therapy with three different TNF-\u03b1 blocking agents in rheumatoid arthritis. Clin Exp Rheumatol. 2009;27:333\u2013336.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_14_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21306"},{"key":"e_1_3_14_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10697"},{"key":"e_1_3_14_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201544"},{"issue":"5","key":"e_1_3_14_7_1","first-page":"S128","article-title":"Urticaria and angioedema in a patient with Beh\u00e7et\u2019s disease treated with adalimumab","volume":"24","author":"S\u00e0nchez-Cano D","year":"2006","unstructured":"S\u00e0nchez-Cano D, Callejas-Rubio JL, Ortego-Centeno N, et al. Urticaria and angioedema in a patient with Beh\u00e7et\u2019s disease treated with adalimumab. Clin Exp Rheumatol. 2006;24(5 Suppl 42):S128.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_14_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes130"},{"key":"e_1_3_14_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2011.03.014"},{"key":"e_1_3_14_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.065615"},{"key":"e_1_3_14_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201544"},{"key":"e_1_3_14_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202220"},{"key":"e_1_3_14_13_1","doi-asserted-by":"publisher","DOI":"10.1203\/PDR.0b013e318208451d"},{"key":"e_1_3_14_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201445"},{"key":"e_1_3_14_15_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.079277"},{"key":"e_1_3_14_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.057406"},{"key":"e_1_3_14_17_1","volume-title":"Monoclonal antibodies, immunogenicity, and associated infusion reactions","author":"Cheifetz A","year":"2005","unstructured":"Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. New York (NY): Mount Sinai Medical Center; 2005."},{"key":"e_1_3_14_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21909"},{"key":"e_1_3_14_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e318180e300"},{"key":"e_1_3_14_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00238-1"},{"key":"e_1_3_14_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.123"},{"key":"e_1_3_14_22_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2014.970165"},{"key":"e_1_3_14_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.21185"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/14740338.2016.1112375","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T10:54:51Z","timestamp":1770893691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/14740338.2016.1112375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,11]]},"references-count":94,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1,2]]}},"alternative-id":["10.1517\/14740338.2016.1112375"],"URL":"https:\/\/doi.org\/10.1517\/14740338.2016.1112375","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-11-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}